|
41 |
18F-FDG-PET-MRI for the assessment of acute intestinal graft-versus-host-disease (GvHD)
Enthalten in BMC cancer Bd. 21, 10.9.2021, Nr. 1, date:12.2021: 1-10
|
|
|
|
42 |
Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Enthalten in Bone marrow transplantation Bd. 59, 30.3.2024, Nr. 7, date:7.2024: 983-990
|
|
|
|
43 |
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries
Enthalten in Leukemia Bd. 38, 6.3.2024, Nr. 4, date:4.2024: 810-821
|
|
|
|
44 |
Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis
Enthalten in Annals of hematology Bd. 102, 7.2.2023, Nr. 4, date:4.2023: 755-760
|
|
|
|
45 |
Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002
Enthalten in Bone marrow transplantation Bd. 58, 25.9.2023, Nr. 12, date:12.2023: 1416-1418
|
|
|
|
46 |
Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients
Enthalten in Blood cancer journal Bd. 14, 2.5.2024, Nr. 1, date:12.2024: 1-8
|
|
|
|
47 |
How risky is a second allogeneic stem cell transplantation?
Enthalten in Leukemia Bd. 38, 25.6.2024, Nr. 8, date:8.2024: 1799-1807
|
|
|
|
48 |
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
Enthalten in Journal of hematology & oncology Bd. 15, 5.9.2022, Nr. 1, date:12.2022: 1-15
|
|
|
|
49 |
Impact of intensified contact precautions while treating hematopoietic stem cell transplantation recipients during aplasia
Enthalten in European journal of medical research Bd. 28, 15.3.2023, Nr. 1, date:12.2023: 1-6
|
|
|
|
50 |
Loss of CD22 expression and expansion of a CD22dim subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin
Enthalten in Annals of hematology Bd. 100, 31.7.2021, Nr. 11, date:11.2021: 2727-2732
|
|
Administration
